Navigation Links
Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis
Date:6/1/2009

patients in the fourth quarter of 2009, if at all; that DR Cysteamine will increase absorption, require less frequent dosing or improve tolerability relative to the current standard of care; that DR Cysteamine will have a positive effect on cystinosis patients and increase their quality of life; and that any of the Company's clinical and preclinical drug candidates will result in approved therapeutics. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause the Company's actual results to be materially different from these forward-looking statements. Factors which may significantly change or prevent the Company's forward looking statements from fruition include: that Raptor may be unsuccessful at raising funds to continue its development programs; Raptor may be unsuccessful in developing any products or acquiring products; that Raptor's technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; that Raptor is unable to retain or attract key employees whose knowledge is essential to the development of its products; that unforeseen scientific difficulties develop with the Company's process; that Raptor's patents are not sufficient to protect essential aspects of its technology; that competitors may invent better technology; and that Raptor's products may not work as well as hoped or worse, that the Company's products may harm recipients. As well, Raptor's products may never develop into useful products and even if they do, they may not be approved for sale to the public. Raptor cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties, and other factors are described in greater detail in the Company's filings from time to time with the Securities and Exchange Commission (the "SEC"), which Raptor strongly urges you to read and
'/>"/>
SOURCE Raptor Pharmaceuticals Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP)
2. Raptor Pharmaceuticals Expands Board of Directors and Scientific Advisory Board
3. Raptor Pharmaceuticals Closes $10 Million Private Placement
4. Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008
5. Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention
6. Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntingtons Disease
7. Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
8. Raptor Pharmaceuticals Acquires Orphan Clinical Program
9. Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
10. Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study
11. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... Global Stem Cells Group and Stem ... first cellular and regenerative medicine symposium in Barcelona Spain ... stem cell training class Oct. 10. The event will ... of Therapeutic Confrontations (CONFTERA) in Barcelona. , In ... medicine and recent advances in cellular therapies, Global Stem ...
(Date:5/26/2015)... , May 26, 2015  A simple blood test ... Center to detect early Alzheimer,s disease is a step ... Detailed standardized guidelines that are needed before a ... published in Alzheimer,s & Dementia . The guidelines ... international working group that includes UNT Health Science Center. ...
(Date:5/26/2015)... , 26. mája 2015 ... mene svojej rodiny prezidentom Barackovi Obamovi a Billovi ... súvislosti so stratou Dr. Rongxiang Xu , ... http://photos.prnewswire.com/prnh/20150522/218111 Dr. Xu bol pionier, ... a jeho odhodlanie v oblasti vedy a príkladné ...
(Date:5/26/2015)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... the development of oral drug delivery systems, announced today ... company,s Phase IIb trial of ORMD-0801, its oral insulin ... The submission was made under the company,s existing Investigational ... study of ORMD-0801 for type 2 diabetics is designed ...
Breaking Biology Technology:Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 2Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 3Guidelines bring UNT Health Science Center's blood test for Alzheimer's one step closer 2Dr. Rongxiang Xu, O legende 2Oramed Submits Protocol to U.S. FDA for Its Phase IIb Oral Insulin Study 2Oramed Submits Protocol to U.S. FDA for Its Phase IIb Oral Insulin Study 3
... ( www.investoruprising.com ) has released "A Guide to Biotech ... Exchange Traded Funds (ETFs) and mutual funds, which is ... (Logo: http://photos.prnewswire.com/prnh/20110411/NY80781LOGO-a) "A Guide to ... the leading biotech mutual funds and ETFs. It explains ...
... 1, 2011 Tioga Pharmaceuticals, Inc. announced today that ... designation by the U.S. Food and Drug Administration (FDA) ... syndrome (D-IBS). Tioga is conducting a multi-center Phase 3 ... Special Protocol Assessment agreement with the FDA for U.S. ...
... NEW YORK, June 1, 2011 Reportlinker.com ... is available in its catalogue: ... companies http://www.reportlinker.com/p0350354/Biochips-and-Microarrays---Technologiesmarkets-and-companies.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Genomics ... of biochip/microarray markets based on technologies and ...
Cached Biology Technology:Investor Uprising Publishes Free Biotech Investment Report 2Investor Uprising Publishes Free Biotech Investment Report 3FDA Grants Fast Track Designation to Tioga Pharmaceuticals' Asimadoline for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome 2Reportlinker Adds Biochips and Microarrays - Technologies, markets and companies 2Reportlinker Adds Biochips and Microarrays - Technologies, markets and companies 3
(Date:5/5/2015)... 5, 2015, NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, reminds investors and media that ... is presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series ... is themed Global Fraud: Where is the Trust in ...
(Date:4/21/2015)... 21, 2015 High crime ... are boosting access control systems market in ... a recently published report by TechSci Research " Saudi ... access control systems market in Saudi Arabia ... 2020.The access control systems market in the Kingdom is ...
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. ... Online (FIDO ® ) Alliance tm , an ... FIDO members commit to share technology and collaborate ... that are interoperable, more secure and private, and ... biometric identity verification that protects sensitive user information ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... is shaped by evolution through environmental pressures and ... other ways very similar might respond to their ... differently, using photoreceptors that are attuned to particular ... of closely-related fish species inhabiting the Great Lakes ...
... potential new treatment for stroke has taken a major step ... Researchers at The University of Manchester have shown in laboratory ... cells from injury and death. , The team, led by ... the results of the first small trial of IL-1ra in ...
... have demonstrated how the microenvironments of two human ... metastatic melanoma cells to revert to a normal, ... colonies similar to hESCs. The researchers also showed ... culture on the microenvironments of hESCs. , "Our ...
Cached Biology News:Multiple genes permit closely related fish species to mix and match their color vision 2Stroke treatment a step closer after trial 2Stem cell microenvironment reverses malignant melanoma 2
Mouse NOV/CCN3 Affinity Purified Polyclonal Ab...
HiTrap NHS-activated HP, 1 x 5 ml. Category: Chromatography Systems & Accessories, Systems....
Human CXCL14/BRAK Affinity Purified Polyclonal Ab...
mIGSF4A Aff Pur PAb...
Biology Products: